Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
Not Applicable
Completed
- Conditions
- Infertility
- Interventions
- Other: Medium Supplemented with Latrunculin A
- Registration Number
- NCT03678818
- Lead Sponsor
- Ibn Sina Hospital
- Brief Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
- ICSI participants
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Handling Medium Supplemented with Latrunculin A Medium Supplemented with Latrunculin A -
- Primary Outcome Measures
Name Time Method oocyte survival rate 6 days of culture
- Secondary Outcome Measures
Name Time Method fertilization rate 6 days of culture Blastocyst formation rate 6 days of culture Blastocyst quality rate 6 days of culture Clinical pregnancy rate three months Implantation rate 7 weeks Ongoing pregnancy rate 12 weeks
Trial Locations
- Locations (2)
Banon Assiut
🇪🇬Assiut, Egypt
IbnSina IVF Center
🇪🇬Sohag, Egypt